CD19 and Parkinson disease: In PD with Levodopa group, the percentage of cTfh cells was significantly higher in PD patients (P < 0.0001, Figure 6C), the percentage of CD19+ B cells among PBMCs was significantly lower in PD patients (P = 0.006, Figure 6D).